IP Library › Granted Patent US 11,938,228
Granted Patent B2
US 11,938,228 · App. 16/241,408 · Granted Mar 26, 2024

Particle-based multi-layer therapeutic delivery device and method

Inventors: Manijeh Nazari Goldberg (Newburyport, MA); Brandon LaPorte (Methuen, MA); Aaron Manzi (Atkinson, NH); Amritpreet Birdi (Peabody, MA)
Assignee: PRIVO TECHNOLOGIES, INC.
A61K9/70A61K9/0014A61K9/006A61K9/107A61K9/167A61K9/2077A61K9/2086A61K9/209A61K31/616A61K47/02A61K47/36A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,938,228
App. No.
16/241,408
Granted
Mar 26, 2024
Kind
B2
Abstract

A device for delivery of a first therapeutic agent and a second therapeutic agent to a site in epithelial tissue includes a first layer having a first, freeze-dried polymeric matrix having first and second opposed surfaces, formed by a composition including chitosan, a hydration promoter, a particle adhesion inhibitor, and a particle aggregation inhibitor, and a plurality of first particles embedded within the first matrix so as to be directly surrounded by, and in contact with, the first matrix, the first particles containing the first therapeutic agent and having a coating around the first therapeutic agent, the coating including chitosan. The device further includes a second layer, adjacent to the first layer, having a second, freeze-dried polymeric matrix containing the second therapeutic agent, the first layer and/or the second layer is configured to be attached to the site in the epithelial tissue.

Claims (18)

1. A device for delivery of a first therapeutic agent and a second therapeutic agent to a site in epithelial tissue, the device comprising:

a first layer comprising:

a first porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the first matrix formed by a composition comprising chitosan, a hydration promoter, a particle adhesion inhibitor comprising hydroxypropylmethylcellulose (HPMC), a particle aggregation inhibitor in a concentration from 1% to 10% by weight of the first layer, and a free amount of the first therapeutic agent,

wherein the hydration promoter is selected from the group consisting of ethylene glycol, propylene glycol, beta-propylene glycol, and combinations thereof,

wherein the particle aggregation inhibitor is sucralose, and

a plurality of first particles embedded within the first matrix so as to be directly surrounded by, and in contact with, the first matrix, the first particles encapsulating the first therapeutic agent and comprising chitosan so as to provide controlled release of the first therapeutic agent from the first particles through one of the opposed surfaces of the first matrix, wherein the average diameter of the plurality of first particles is from about 500 nm to about 2000 nm; the first particles further comprising sodium tripolyphosphate, and

a second layer, adjacent to the first layer, the second layer comprising:

a second, freeze-dried polymeric matrix having third and fourth opposed surfaces, the second matrix formed by a composition comprising chitosan and a plurality of second particles embedded within the second matrix, wherein the second particles comprise the second therapeutic agent,

wherein the first surface of the first layer is configured to be attached to the site in the epithelial tissue,

wherein the second surface of the first layer is attached to the third surface of the second layer,

wherein the fourth surface of the second layer is covered with a covering selected from the group consisting of a film, a layer, and a membrane, the covering being configured to restrict passage of any therapeutic agent through the fourth surface of the second layer while still being water permeable, and

wherein at least one of the first therapeutic agent and second therapeutic agent is cisplatin.

2. A device according to claim 1 , wherein the second particles comprise positively charged chitosan.

3. A device according to claim 1 , wherein one or both of the opposed surfaces of the first matrix is permeable to water.

4. A device according to claim 1 , wherein one or both of the opposed surfaces of the second matrix is permeable to water.

5. A device according to claim 1 , wherein the first therapeutic agent and the second therapeutic agent are the same therapeutic agent.

6. A device according to claim 1 , wherein the first particles are made from pure chitosan.

7. A device according to claim 1 , wherein a layer selected from the group consisting of the first layer, the second layer, and combinations thereof, includes a pain mitigator, wherein the pain mitigator is present in a form selected from the group consisting of free, encapsulated, and combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2019
From: GOLDBERG, MANIJEH NAZARI; MANZI, AARON; LAPORTE, BRANDON; BIRDI, AMRITPREET
To: PRIVO TECHNOLOGIES, INC.
Reel/Frame 048176/0311 →
Continuity (3)
Division 15932315 · Feb 16, 2018
Provisional Application 62460665 · Feb 17, 2017
Related Publication 20190142760A1 · May 16, 2019